Tag: organ

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

InnovAge Florida PACE – Tampa and Tampa General Hospital Form Joint Venture to Elevate PACE Services in Tampa

Young Mother’s Battle with Arthritis Highlights Need for Timely Access to Modern Medications in BC

VANCOUVER, BC, Aug. 14, 2025 /CNW/ - Eileen Davidson, a Burnaby mother and advocate, is calling on the BC government to modernize its approach to...

Emmaus Life Sciences Reports Quarterly Financial Results

TORRANCE, Calif., Aug. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell...

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market

Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market

Am Weltorganspendetag gibt das KFSHRC die Durchführung von 10 Nierentransplantationen innerhalb von 48 Stunden bekannt

RIAD, Saudi-Arabien, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Das King Faisal Specialist Hospital and Research Centre (KFSHRC) hat an zwei aufeinanderfolgenden Tagen erfolgreich 10 Cross-Over-Nierentransplantationen durchgeführt und damit einen weltweiten Rekord für die meisten derartigen Eingriffe innerhalb von zwei Tagen in einem einzigen Zentrum aufgestellt – zeitgleich mit dem Weltorganspendetag am 13. August. Dieser Meilenstein unterstreicht die führende Rolle des KFSHRC im Bereich der Organtransplantation weltweit.

On World Organ Donation Day KFSHRC Announces 10 Kidney Exchange Transplants Completed in 48 Hours

RIYADH, Saudi Arabia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) successfully performed 10 kidney exchange transplants over two consecutive days, setting a global record for the highest number of such procedures conducted within a two-day span at a single center, coinciding with World Organ Donation Day on August 13. This milestone reinforces KFSHRC’s position as a global leader in organ transplantation.

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren’s Syndrome in China

YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met...

Greenlight for Internet Resilience Framework sets Africa on path to reliable networks

NAIROBI, Kenya, Aug. 13, 2025 /PRNewswire/ -- Africa's telecom leaders have called on governments and regulators to adopt and nationalise a Model Framework for Building...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in...

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR

XORTX Completes USD $114,500 Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

New Data Analyses from Groundbreaking Pivotal Bridge to HOPE Clinical Trial Demonstrate Statistically Significant Clinical, Economic and Immunomodulatory Advantages in Liver Transplantation

Presentations showcased at World Transplant Congress in San Francisco demonstrate HOPE reduces the cost of liver transplantation by shortening the index hospitalization and decreasing...

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress

Wuppertal, Germany, August 5, 2025 - Aicuris Anti-infective Cures AG today announced initial clinical data from its ongoing first-in-human Phase 1 trial with AIC468. The novel antiviral antisense oligonucleotide is in development for the treatment of BK virus (BKV) infections in kidney transplant recipients. The interim results, presented at the World Transplant Congress in San Francisco on August 4, 2025, provide an overview of PK characteristics of AIC468 from the Phase 1 clinical trial in healthy volunteers.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsOrgan

MEDIA ADVISORY – ONA Nursing Homes Members Demand Fair Wages, Safe Working Conditions During Province-wide Information Pickets

Glenn Agre Bergman & Fuentes Builds Out Structured Financial Products Litigation Practice with New Lateral Partner

AMERICAN SKIN ASSOCIATION ANNUAL GALA RECOGNIZES SUN PHARMA WITH CORPORATE LEADERSHIP AWARD

Tag: organ

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

InnovAge Florida PACE – Tampa and Tampa General Hospital Form Joint Venture to Elevate PACE Services in Tampa

Young Mother’s Battle with Arthritis Highlights Need for Timely Access to Modern Medications in BC

Emmaus Life Sciences Reports Quarterly Financial Results

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

Am Weltorganspendetag gibt das KFSHRC die Durchführung von 10 Nierentransplantationen innerhalb von 48 Stunden bekannt

On World Organ Donation Day KFSHRC Announces 10 Kidney Exchange Transplants Completed in 48 Hours

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren’s Syndrome in China

Greenlight for Internet Resilience Framework sets Africa on path to reliable networks

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

XORTX Completes USD $114,500 Private Placement

New Data Analyses from Groundbreaking Pivotal Bridge to HOPE Clinical Trial Demonstrate Statistically Significant Clinical, Economic and Immunomodulatory Advantages in Liver Transplantation

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us